Почетна › Hronična mijelomonocitna leukemija › Тексас
Kliničke studije za Hronična mijelomonocitna leukemija u državi Тексас
18 studija za Hronična mijelomonocitna leukemija traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст од 15 до 80 · Оба пола · Ажурирано 2. 11. 2026. · NCT02727803Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07128381Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- AIR Care, Dallas
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT07143669A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT03896269Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04140487(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2Здраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 11. 9. 2026. · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 4. 9. 2026. · NCT03383575Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07033598Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2/3Здраве особе су добродошле
Узраст од 18 до 70 · Оба пола · Ажурирано 11. 8. 2026. · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст од 12 до 80 · Оба пола · Ажурирано 7. 8. 2026. · NCT05092451A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 20. 5. 2026. · NCT04239157A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
Тражи се учесникФаза 2
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 12 и старији · Оба пола · Ажурирано 16. 3. 2026. · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT06950034Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- MD Anderson Cancer Center, Huston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2025. · NCT03850574Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.